ArticleCancer immunology, immunotherapy : CII2017
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Open access · hybridAbstract readClinical Trial, Phase I
In one paragraph
Article in Cancer immunology, immunotherapy : CII, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 248 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
248citing papers in PubMed, 2 pooled it
14.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
248 citing papers in PubMed, 2 syntheses or guidelines pooled it, 403 citations in OpenAlex.
- The safety and efficacy of chimeric antigen receptor-T cell therapy in solid malignancies: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis.Cancer immunology, immunotherapy : CII · 2023Pooled it
- Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial.Oncoimmunology · 2020Trial
- Engineering CAR-T cell therapies for digestive tract cancer: advances, challenges, and strategies to overcome tumor heterogeneity and immunosuppressive barriers.Neoplasia (New York, N.Y.) · 2026Review
- Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Dual-recognizing antibodies targeting CEACAMs in the tumor microenvironment: towards more precise targeting.Cell communication and signaling : CCS · 2026Review
- Spatial Regulation of CAR Signaling Enables Logic-Gated Activity.bioRxiv : the preprint server for biology · 2026Article
- Bioinspired oxidized mRNA lipid nanoparticles for ex vivo engineering of chimeric antigen receptor macrophages targeting solid tumors.Bioengineering & translational medicine · 2026Article
- Adoptive T-cell therapies in the clinic.Bioengineering & translational medicine · 2026Review
- Prognostic value of carcinoembryonic antigen kinetics in predicting distant metastatic recurrence of breast cancer: a multicenter cohort study.Annals of surgical treatment and research · 2026Article
- Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial.Nature cancer · 2026Article
- Enzymatic Remodelling of Tumour Microenvironment Enhances Anti-CEACAM5 CAR T-Cell Efficacy Against Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Sensitive CAR T cells redefine targetable CD70 expression in solid tumors.Science (New York, N.Y.) · 2026Article
- DSG2-Directed CAR-T Cells Safely and Universally Eliminate Solid Tumors.Research square · 2026Article
- Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Tailored strategies for improved control of CAR-T cells in multiple myeloma.Frontiers in immunology · 2026Article
- CAR-T cell therapy for pancreatic cancer: Translating emerging targets and dual-targeting strategies from solid tumors.Frontiers in immunology · 2026Review
- Monoclonal Antibodies and Derivatives: Therapeutic Tools for Cancer.Oncology research · 2026Review
- Advancing Cancer Immunotherapy: Chimeric Antigen Receptor (CAR)-T Cell Engineering through Novel Screening Methods.Biomolecules & therapeutics · 2026Review
- Oncofetal antigens as emerging targets in chimeric antigen receptor (CAR)-T cell-based immunotherapies: opportunities and challenges.Frontiers in cell and developmental biology · 2026Review
188 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 1 country.
Fiona C ThistlethwaiteDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Wilmslow Road, Withington, Manchester, M20 4BX, UK. fiona.thistlethwaite@christie.nhs.uk.
David E GilhamFaculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Healthcare Science Centre, Wilmslow Road, Withington, Manchester, UK.
Ryan D GuestFaculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Healthcare Science Centre, Wilmslow Road, Withington, Manchester, UK.
Dominic G RothwellClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Withington, Manchester, UK.
Manon PillaiDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Wilmslow Road, Withington, Manchester, M20 4BX, UK.
Deborah J BurtClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Withington, Manchester, UK.
Andrea J ByatteDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Wilmslow Road, Withington, Manchester, M20 4BX, UK.
Natalia KirillovaFaculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Healthcare Science Centre, Wilmslow Road, Withington, Manchester, UK.
Juan W ValleDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Wilmslow Road, Withington, Manchester, M20 4BX, UK.
Surinder K SharmaUniversity College London (UCL) Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, UK.
Kerry A ChesterUniversity College London (UCL) Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, UK.
Nigel B WestwoodCancer Research UK Centre for Drug Development, Angel Building, 407 St John Street, London, UK.
Sarah E R HalfordCancer Research UK Centre for Drug Development, Angel Building, 407 St John Street, London, UK.
Stephen NabarroCancer Research UK Centre for Drug Development, Angel Building, 407 St John Street, London, UK.
Susan WanCancer Research UK Centre for Drug Development, Angel Building, 407 St John Street, London, UK.
Eric AustinStem Cells and Immunotherapy, National Health Service Blood and Transplant (NHSBT) Liverpool Centre, Speke, Liverpool, UK.
Robert E HawkinsDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Wilmslow Road, Withington, Manchester, M20 4BX, UK.
University of Manchester · GBCancer Research UK · GBThe Christie NHS Foundation Trust · GBCancer Research UK Manchester Institute · GBCellular Therapeutics (United Kingdom) · GBCRUK Lung Cancer Centre of Excellence · GBManchester Academic Health Science Centre · GBNational Health Service · GBUniversity College London · GB
Funding
No grant is acknowledged in the PubMed record.
Abstract
The primary aim of this clinical trial was to determine the feasibility of delivering first-generation CAR T cell therapy to patients with advanced, CEACAM5
Indexed as
Abdominal PainAdultAgedAnemiaCarcinoembryonic AntigenCohort StudiesCyclophosphamideDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticGPI-Linked ProteinsHumansImmunotherapy, AdoptiveInterferon-gammaInterleukin-6LungCarcinoembryonic AntigenCEACAM5 protein, humanCyclophosphamidefludarabineGPI-Linked ProteinsInterferon-gammaInterleukin-6Myeloablative AgonistsReceptors, Antigen, T-CellVidarabineCEAChimeric antigen receptorPersistenceT cellsToxicity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.